Atara Biotherapeutics, Inc. (NASDAQ: ATRA) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating.
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $25.00 price target on the stock.
Updated Results of Phase 3 ALLELE Study Presented at 66th American Society of Hematology Annual Meeting Confirm Efficacy, Safety and Durability of Novel Allogeneic Cell Therapy Tabelecleucel in Relapsed or Refractory Epstein-Barr Virus Positive Post-Trans
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) was upgraded by analysts at TD Cowen to a "strong-buy" rating.
Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference